






0300

 TRANSMITTAL LETTER (General - Patent Pending)		Docket No. 11375Z				
In Re Application Of: Andrea M. Douglas, et al.						
Serial No. 09/819,097	Filing Date March 5, 2001	Examiner Unassigned	Group Art Unit Unassigned			
Title: CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER						
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>						
Transmitted herewith is: Response to the Notice to Comply dated October 2, 2001; Copy of the Notice to Comply; Paper Copy of Sequence Listing; Diskette containing computer readable copies of Sequence Listing; and Statement Under 37 CFR 1.821(f)						
in the above identified application.						
<input checked="" type="checkbox"/> No additional fee is required. <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.						
<input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required.						
 _____ <i>Signature</i>		Dated: Dec. 3, 2001 (Monday)				
Leopold Presser Registration No. 19,827 SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 5px;"> I certify that this document and fee is being deposited on 12/3/01 (Mon) with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. </td> </tr> <tr> <td style="text-align: center; padding: 5px;">  <i>Signature of Person Mailing Correspondence</i> </td> </tr> <tr> <td style="text-align: center; padding: 5px;"> Mishelle Mustafa <i>Typed or Printed Name of Person Mailing Correspondence</i> </td> </tr> </table>		I certify that this document and fee is being deposited on 12/3/01 (Mon) with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	 <i>Signature of Person Mailing Correspondence</i>	Mishelle Mustafa <i>Typed or Printed Name of Person Mailing Correspondence</i>
I certify that this document and fee is being deposited on 12/3/01 (Mon) with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.						
 <i>Signature of Person Mailing Correspondence</i>						
Mishelle Mustafa <i>Typed or Printed Name of Person Mailing Correspondence</i>						
FSD/PIB/JAM:sf CC:						



#6

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicants:** Andrea M. Douglas, et al.**Examiner:** Unassigned**Serial No.:** 09/819,097**Art Unit:** Unassigned**Filed:** March 5, 2001**Docket:** 11375z**For:** CYTOKINES AND THEIR USE
IN TREATMENT AND/OR PROPHYLAXIS
OF BREAST CANCER**Dated:** December 3, 2001 (Monday)Assistant Commissioner for Patents
Washington, DC 20231**Response to Notice to Comply under 37 C.F.R. §1.821**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated October 2, 2001 and in accordance with the provisions in 37 C.F.R. §1.821, Applicants submit herewith an initial paper and an initial computer readable copy of the Sequence Listing, along with a Statement Under 37 C.F.R. §1.821(f), stating that these copies are identical. A copy of the


CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on December 3, 2001 (Monday).

Dated: December 3, 2001 (Monday)
Michelle Mustafa

Notice to Comply is also enclosed. Applicants respectfully submit that the content of the initial paper and initial computer copies of the sequence listing do not introduce new matter.


Respectfully submitted,



Leopold Presser
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

FSD/PIB/JAM:sf



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/819,097	03/05/2001	Andrea Margaret Douglas	11375Z

CONFIRMATION NO. 6127

FORMALITIES LETTER



OC000000006830968

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530

Date Mailed: 10/02/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE